Pontifax Late Stage Fund L.P.
Insider CIK 1793769 · KROS 10% owner · ETNB 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 1,121,045 | $17.75 | $19.90M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 1,226,412 | $17.75 | $21.77M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 155,262 | $17.75 | $2.76M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 2,284,612 | $17.75 | $40.55M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 1,914 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 3,539 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 1,723 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 1,723 | — | $0 | 1,121,045 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 3,539 | — | $0 | 2,284,612 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 1,914 | — | $0 | 1,226,412 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 26,634 | $50.00 | $1.33M | 2,288,151 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 12,966 | $50.00 | $648.3K | 1,122,768 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 14,400 | $50.00 | $720.0K | 1,228,326 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 6,000 | $50.00 | $300.0K | 155,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 6,000 | $50.00 | $300.0K | 155,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 14,400 | $50.00 | $720.0K | 1,228,326 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 12,966 | $50.00 | $648.3K | 1,122,768 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 26,634 | $50.00 | $1.33M | 2,288,151 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 12,966 | $50.00 | $648.3K | 1,122,768 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 14,400 | $50.00 | $720.0K | 1,228,326 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 6,000 | $50.00 | $300.0K | 155,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 26,634 | $50.00 | $1.33M | 2,288,151 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 82,425 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 737,226 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 663,825 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 1,363,542 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 36,858 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 68,654 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 163,612 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 88,460 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 79,653 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 169,307 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 91,538 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 105,000 | $16.00 | $1.68M | 1,213,926 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 94,546 | $16.00 | $1.51M | 1,109,802 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 194,203 | $16.00 | $3.11M | 2,261,517 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 36,858 | — | $0 | 105,512 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 79,653 | — | $0 | 1,108,926 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 88,460 | — | $0 | 1,015,256 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 163,612 | — | $0 | 2,067,314 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 68,654 | — | $0 | 68,654 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 91,538 | — | $0 | 1,029,273 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 82,425 | — | $0 | 926,796 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 169,307 | — | $0 | 1,903,702 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 737,226 | — | $0 | 937,735 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 43,750 | $16.00 | $700.0K | 149,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 663,825 | — | $0 | 844,371 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 1,363,542 | — | $0 | 1,734,395 | SEC↗ |
| ETNB 89bio, Inc. | C Conversion deriv | 2019-11-13 | 2019-11-13 | 5,500,001 | — | $0 | 0 | SEC↗ |
| ETNB 89bio, Inc. | C Conversion | 2019-11-13 | 2019-11-13 | 884,671 | — | $0 | 1,134,671 | SEC↗ |
| ETNB 89bio, Inc. | P Buy | 2019-11-11 | 2019-11-13 | 250,000 | $16.00 | $4.00M | 250,000 | SEC↗ |